Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease …
AA Kolkailah, I Lingvay… - Diabetes, Obesity …, 2023 - Wiley Online Library
2 METHODS Patients included in the SUSTAIN-6 trial had T2D and, those who were aged≥
50 years had prevalent CVD (defined as previous CV, cerebrovascular or peripheral …
50 years had prevalent CVD (defined as previous CV, cerebrovascular or peripheral …
[引用][C] Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular …
AA Kolkailah, I Lingvay… - Diabetes …, 2023 - utsouthwestern.elsevierpure.com
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in
patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the …
patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the …
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease …
AA Kolkailah, I Lingvay… - Diabetes, obesity & …, 2023 - pubmed.ncbi.nlm.nih.gov
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in
patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the …
patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the …
[HTML][HTML] Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for …
AA Kolkailah, I Lingvay, I Dobrecky-Mery… - Diabetes, obesity & …, 2023 - ncbi.nlm.nih.gov
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) with proven
cardiovascular (CV) benefits are recommended in patients with type 2 diabetes (T2D) with …
cardiovascular (CV) benefits are recommended in patients with type 2 diabetes (T2D) with …
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease …
AA Kolkailah, I Lingvay, I Dobrecky-Mery… - Diabetes, Obesity & …, 2022 - europepmc.org
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) with proven
cardiovascular (CV) benefits are recommended in patients with type 2 diabetes (T2D) with …
cardiovascular (CV) benefits are recommended in patients with type 2 diabetes (T2D) with …
[引用][C] Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for …
AA Kolkailah, I Lingvay, I Dobrecky-Mery… - Diabetes, Obesity & …, 2022 - europepmc.org
Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in
Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the …
Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the …